OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
- Orchestra Bio 近 90 天出现 3 次
- Orchestra Bio 近 90 天第 3 次收购
- 上一次：同一天稍早 · OpenAI acquires Orchestra Bio to bring AI agents into drug development
发生了什么
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
摘要按规则整理自下方来源原文